This site will look much better in a browser that supports web standards, but it is accessible to any browser or Internet device.
This section of the Androderm® Web site is technical in nature containing product prescribing information, and is intended for US Healthcare Professionals only.
Yes: I am a US Healthcare Professional. Enter this section.
No: I am not a US Healthcare Professional. Return to main menu.
Androderm® is an androgen indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
IMPORTANT SAFETY INFORMATION
Androderm® should not be used in men with carcinoma of the breast, known or suspected carcinoma of the prostate, or patients with pre-existing cardiac, renal, or hepatic disease. Androderm® should also not be used in pregnant or breastfeeding women, as testosterone may cause fetal harm. Patients with benign prostatic hyperplasia (BPH) should be monitored for worsening signs and symptoms, and exposure of Androderm® to women or children should be avoided. Exogenous administration of testosterone may lead to azoospermia, and sleep apnea may occur in those with risk factors. Patients should be monitored for prostate specific antigen (PSA), liver function, lipid concentrations, hematocrit, and hemoglobin. In a clinical study of 36 patients treated with Androderm®, skin irritation from the patch was the most common adverse event (pruritus at application site [17%]), followed by application site vesicles (6%), and back pain (6%).
Please see full Prescribing Information.
Models are for illustrative purposes only.